On July 25, 2025, Inmagene Biopharmaceuticals successfully completed its reverse merger with Ikena Oncology, Inc. The combined entity has been officially renamed ImageneBio, Inc. ("Imagene") and was successfully listed on the Nasdaq Stock Market under the ticker symbol "IMA" on July 28, 2025.
Imagene's core asset is IMG-007, a monoclonal antibody targeting OX40, which is currently undergoing a Phase 2b clinical trial for the treatment of moderate-to-severe atopic dermatitis. Through the reverse merger and PIPE financing, Imagene has raised over USD 175 million in total. IMG-007 is expected to offer a differentiated treatment option for patients with atopic dermatitis and has the potential to be expanded into additional immunology-related indications. As an important strategic extension of Imagene, Miragene was officially spun off from its parent company upon the completion of the transaction and has now commenced independent operations. Apart from IMG-007, all other product pipelines, collaboration projects, and the "Smart Innovation" platform previously under Imagene have been transferred in full to Miragene.
Han Kun acted as PRC legal counsel for Imagene in this transaction and provided professional and efficient legal services throughout the reverse merger and the spin-off of Miragene.
